From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Clinical data
Other namesAS-902330; rhFGF18; L-Methionyl(human fibroblast growth factor 18 (FGF-18, zFGF5)-(1-169)-peptide)[1]:45
CAS Number
Chemical and physical data
Molar mass19832.6262 g/mol g·mol−1
3D model (JSmol)

Sprifermin (INN) (developmental code name AS-902330), also known as recombinant human fibroblast growth factor 18 (rhFGF18), is a recombinant form of human fibroblast growth factor 18 (FGF18)[1]:45 which is under development by Merck and Nordic Bioscience for the treatment of osteoarthritis.[2] As a recombinant form of FGF18, sprifermin is a potent agonist of the FGFR2 and FGFR3.[3][4]

As of 2017, the drug is in phase II clinical trials for the treatment of osteoarthritis.[2][5]


  1. ^ a b http://www.who.int/medicines/publications/druginformation/innlists/INNprepub105.pdf
  2. ^ a b http://adisinsight.springer.com/drugs/800017598
  3. ^ Kim E. Barrett; Fayez K. Ghishan; Juanita L. Merchant; Hamid M. Said, Jackie D. Wood (10 May 2006). Physiology of the Gastrointestinal Tract. Academic Press. pp. 216–. ISBN 978-0-08-045615-7.
  4. ^ Hamid M. Said (4 July 2012). Physiology of the Gastrointestinal Tract, Two Volume Set. Academic Press. pp. 235–. ISBN 978-0-12-382027-3.
  5. ^ A Study to Investigate the Safety and Effectiveness of Different Doses of Sprifermin (AS902330) in Patients With Osteoarthritis of the Knee (FORWARD)

External links[edit]